Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.67 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isatoribine SCHEMBL12808801 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL1758185 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL8664086 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL10148062 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL12112066 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL23475855 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL10117797 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL6905340 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL1276851 | 0.99 | PNP (0.65) | PNPTLR7MEN1KMT2ACYP3A4 | |
| SCHEMBL6976713 | 0.91 | TLR7 (0.57) | PNPTLR7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-1824482-B1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2561872-A1 | 3, 5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof | Anadys Pharmaceuticals, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8097718-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097718-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7560544-B2 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560544-B2 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-0636372-B1 | Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives | ICN PHARMACEUTICALS (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0348446-B1 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES | UNIV BRIGHAM YOUNG (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0636372-A1 | Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives | BRIGHAM YOUNG UNIVERSITY (US) | 1995-02-01 | — | — | EP | disclosed |
| EP-0348446-A4 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES | — | 1991-09-25 | — | — | EP | disclosed |
| US-5041426-A | Viricides, antitumor agents | BRIGHAM YOUNG UNIVERSITY (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0348446-A1 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES. | UNIV BRIGHAM YOUNG (US) | 1990-01-03 | — | — | EP | disclosed |
| WO-1989005649-A1 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES | BRIGHAM YOUNG UNIVERSITY (US) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | TLR5, THPO, IDO1 | PNP 332/4885TLR7 8/4885MEN1 3851/4885 |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | TLR5, THPO, IDO1 | PNP 332/4885TLR7 8/4885MEN1 3851/4885 |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | TLR5, THPO, IDO1 | PNP 332/4885TLR7 8/4885MEN1 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.